{"disease":{"id":"seizure-absence","name":"seizure absence"},"drugs":{"marketed":[{"drug_id":"valproate","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Valproate","company_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its anti-epileptic effects."},{"drug_id":"valproate-sodium","indication_name":"Multiple Seizure Types Including Absence Seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VALPROATE SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Valproate may increase brain GABA levels to exert its antiepileptic effects."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04615442","title":"ECV - Epihunter Clinical Validation","phase":"NA","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Epihunter NV","has_results":false},{"nct_id":"NCT06093490","title":"Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Eysz, Inc.","has_results":false},{"nct_id":"NCT00144872","title":"LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"GlaxoSmithKline","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}